Watch TRDA. Know when insiders buy.
One email the day a filing lands. Free.
TRDA
Entrada Therapeutics, Inc.
4.65
−0.34 −6.81%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
39
FLAG · insiders 25, shorts 52
Insiders, 90 days
−$7.2M
net selling · 0 buys, 24 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $181.1MP/E —DIV YIELD —FCF YIELD -74.20%REV TTM $4.7M −94.1%NET INCOME −$165.8MNET CASH —52W 4.37 – 16.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $898K | −53.9% | — | −$45M | −$42.8M | — | -1.01 | −$32.5M | $11K | −$32.5M | Aug 5 |
| Q1 2026 · Mar 31 | $875K | −95.7% | — | −$42.3M | −$39.7M | — | -0.95 | −$41.7M | $44K | −$41.7M | Aug 5 |
| Q4 2025 · Dec 31derived | $1.3M | −96.5% | — | −$42.2M | −$39.2M | −3562.8% | -0.94 | −$32.2M | −$207K | −$32M | Feb 26 |
| Q3 2025 · Sep 30 | $1.6M | −91.8% | — | −$47.1M | −$44.1M | — | -1.06 | −$28.3M | −$171K | −$28.1M | Nov 6 |
| Q2 2025 · Jun 30 | $1.9M | −97.9% | — | −$46.8M | −$43.1M | −178.3% | -1.04 | −$29.5M | $275K | −$29.8M | Aug 5 |
| Q1 2025 · Mar 31 | $20.6M | −65.2% | — | −$21.8M | −$17.3M | −173.8% | -0.42 | −$38.5M | $1.1M | −$39.7M | Aug 5 |
| Q4 2024 · Dec 31derived | $37.4M | −10.6% | — | −$5.9M | $1.1M | — | -0.04 | −$31.6M | $635K | −$32.2M | Feb 26 |
| Q3 2024 · Sep 30 | $19.6M | −55.3% | — | −$21.7M | −$14M | −139.6% | -0.35 | −$24.3M | $639K | −$24.9M | Nov 6 |
| Q2 2024 · Jun 30 | $94.7M | — | — | $53.4M | $55M | — | 1.55 | $39.8M | $1M | $38.8M | Nov 6 |
| Q1 2024 · Mar 31 | $59.1M | — | — | $21.1M | $23.5M | — | 0.68 | −$25.5M | $838K | −$26.4M | Nov 6 |
| Q4 2023 · Dec 31derived | $41.8M | — | — | $4.9M | −$9.5M | — | -0.28 | −$4M | $976K | −$5M | Feb 27 |
| Q3 2023 · Sep 30 | $43.7M | — | — | $14M | $35.5M | — | 1.02 | −$24.5M | $1.4M | −$25.9M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $25.4M | — | −$157.9M | −$143.8M | -565.5% | -3.47 | −$128.5M | $1M | −$129.6M | — | — |
| FY2024 · to Dec 31 | $210.8M | — | $47M | $65.6M | 31.1% | 1.68 | −$41.6M | $3.2M | −$44.7M | — | — |
| FY2023 · to Dec 31 | $129M | — | −$3.2M | −$6.7M | -5.2% | -0.20 | $139.8M | $5.6M | $134.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$97.2M | −$94.6M | — | -3.02 | −$93.8M | $2.9M | −$96.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$51.1M | −$51.2M | — | -8.16 | −$50.9M | $4.6M | −$55.4M | — | — |
| FY2020 · to Dec 31 | — | — | −$26.7M | −$26.5M | — | -24.00 | −$25.6M | $2.3M | −$27.9M | — | — |
Every number comes from Entrada Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.